Celgene Receives CHMP Positive Opinions for Both REVLIMID (lenalidomide) and IMNOVID (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple...
SUMMIT, N.J.--(BUSINESS WIRE)--Mar 29, 2019--Celgene Corporation (NASDAQ:CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Huma…
